Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: aatkinson who wrote (822)	12/30/1997 11:24:00 AM
From: CARYTRE	Respond to of 1894

Hello to All, All I can say is (the sound of the scream you make when falling). regards C.S.Trecartin

To: aatkinson who wrote (822)	12/30/1997 11:58:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

aatkinson, The quotron system should play the "Taps" tune (that they play at military funerals) when we look at ACMI's chokes - I mean quotes. The small amount of short coverage indicates few shorters. (40K) That is next to nothing. That means that very few shorts are even profitting from the fall. The sellers want out "irregardless" of the price. Panic selling? Panic is the sudden unreasoning and overwhelming fear which attacks people in the face of real or fancied danger. Is the present danger real enough to warrant the present sell-off? Or is it perceived to be? Again someone is buying these shares. Thankfully! The market is saying that this company and all of its proprietary research, market dominance in selected niches, patents, goodwill, inventory and such are only worth $25M. Or roughly five- quarters of their sales. That's only 1.25% of the entire supposed $2 Billion International cytopathology market. AND the revenue numbers for AccuMed have been coming dominantly from the molecular -biology side of the company! With numbers like that you would think that the the rest of the players in the field would be cleaning up the remaining 99% of the market. There not. Even if the actual $2 B potential market was highly over-estimated (doubled) the total U.S. publicly traded players selling or trying to sell into that field haven't made a dent. Efficient market hypothesis states that given all information on the company that investors instantaneously determine its value. Strange how nothing adversely significant has changed in the last month and the market has determined that the Company was valued too excessively. I want to be around when the market figures they have valued it too low. Might be a while the way things are going. There are a lot of 32's, 64'ths, 128'ths down and up from here. Frank